Ovid Therapeutics Inc.
OVID
$2.42
$0.062.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.12M | 7.25M | 6.61M | 6.65M | 548.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.12M | 7.25M | 6.61M | 6.65M | 548.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 7.12M | 7.25M | 6.61M | 6.65M | 548.00K |
| SG&A Expenses | 24.75M | 23.51M | 20.16M | 18.92M | 22.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.86M | 49.09M | 45.08M | 45.82M | 55.16M |
| Operating Income | -47.74M | -41.84M | -38.47M | -39.17M | -54.62M |
| Income Before Tax | -24.17M | -17.41M | -36.33M | -38.18M | -24.97M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.17 | -17.41 | -36.33 | -38.18 | -24.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.17M | -17.41M | -36.33M | -38.18M | -24.97M |
| EBIT | -47.74M | -41.84M | -38.47M | -39.17M | -54.62M |
| EBITDA | -47.57M | -41.57M | -38.05M | -38.60M | -54.00M |
| EPS Basic | -0.24 | -0.26 | -0.50 | -0.53 | -0.34 |
| Normalized Basic EPS | -0.31 | -0.34 | -0.30 | -0.31 | -0.21 |
| EPS Diluted | -0.24 | -0.26 | -0.50 | -0.53 | -0.34 |
| Normalized Diluted EPS | -0.31 | -0.34 | -0.30 | -0.31 | -0.21 |
| Average Basic Shares Outstanding | 360.07M | 294.94M | 284.28M | 284.14M | 283.95M |
| Average Diluted Shares Outstanding | 360.07M | 294.94M | 284.28M | 284.14M | 284.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |